Last reviewed · How we verify
Fesoterodine 8 mg
At a glance
| Generic name | Fesoterodine 8 mg |
|---|---|
| Also known as | Toviaz |
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Fall Prevention in Older Adults With OAB (PHASE4)
- Drug Use Investigation for Toviaz
- BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG (PHASE1)
- A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition (PHASE3)
- Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity. (PHASE3)
- Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE) (PHASE3)
- Fesoterodine on Urgency Episodes in Parkinson's Disease Population (PHASE4)
- Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fesoterodine 8 mg CI brief — competitive landscape report
- Fesoterodine 8 mg updates RSS · CI watch RSS
- Pfizer portfolio CI